Sunday, 31 August 2014

Triple-A syndrome

Triple-A syndrome

Triple A syndrome
Classification and external resources
1471-2415-4-7-1-l.jpg
MRI of the brain of 12 year-old boy with triple-A syndrome showing hypoplastic lacrimal glands (yellow arrows.)
ICD-10E27.4
OMIM231550
DiseasesDB32088
eMedicineped/71
Triple-A syndrome (AAA), also known as Achalasia-Addisonianism-Alacrimia syndrome or Allgrove syndrome,[1] is a rare autosomal recessive congenital disorder. In most cases, there is no family history of it.[2] The syndrome was discovered by Jeremy Allgrove and colleagues in 1978. Triple A stands for achalasia-addisonianism-alacrimasyndrome. Alacrima is usually the earliest manifestation.[3] It is a progressive disorder that can take years to develop the full blown clinical picture.[4]

Characteristics

Individuals affected by AAA have adrenal insufficiency/Addison's disease due to ACTH resistance, alacrima (absence of tear secretion), and achalasia (a failure of a ring of muscle fibers, such as a sphincter, to relax) of the lower esophageal sphincter at the cardia which delays food going to the stomach and causes dilation of the thoracic esophagus. There may also be signs of autonomic dysfunction with AAA, such as pupillary abnormalities, an abnormal reaction to intradermal histamine, abnormal sweating, orthostatic hypotension, and disturbances of the heart rate.[5] Hypoglycemia (low blood sugar) is often mentioned as an early sign.[4] The disorder has also been associated with mild mental retardation.[4]
The syndrome is highly variable. Managed effectively, affected individuals can have a normal lifespan and bear children.

Cause and genetics

Triple-A syndrome is associated with mutations in the AAAS gene, which encodes a protein known as ALADIN (ALacrima Achalasia aDrenal Insuffiency Neurologic disorder).[6][7] In 2000, Huebner et al. mapped the syndrome to a 6 cM interval on human chromosome 12q13 near the type II keratin gene cluster.[8] Since inheritance and gene for the association is known, early diagnosis can allow genetic counseling.[3]

Achalasia

Achalasia



Achalasia
Classification and external resources
Achalasia2010.jpg
A chest X-ray showing achalasia ( arrows point to the outline of the massively dilated esophagus )
ICD-10K22.0
ICD-9530.0
OMIM200400
DiseasesDB72
MedlinePlus000267
eMedicineradio/6 med/16
MeSHC06.405.117.119.500.432
Achalasia (/kəˈlʒə/a- and -chalasia "no relaxation") is a failure of smooth muscle fibers to relax, which can cause a sphincter to remain closed and fail to open when needed. Without a modifier, "achalasia" usually refers to achalasia of the esophagus, which is also called esophageal achalasiaachalasia cardiaecardiospasm, and esophageal aperistalsis. Achalasia can happen at various points along the gastrointestinal tract; achalasia of the rectum, for instance, is Hirschsprung's disease.
Esophageal achalasia is an esophageal motility disorder involving the smooth muscle layer of the esophagus and the lower esophageal sphincter (LES).[1] It is characterized by incomplete LES relaxation, increased LES tone, and lack of peristalsis of the esophagus (inability of smooth muscle to move food down the esophagus) in the absence of other explanations like cancer or fibrosis.[2][3]
Achalasia is characterized by difficulty in swallowingregurgitation, and sometimes chest pain. Diagnosis is reached with esophageal manometry and barium swallow radiographic studies. Various treatments are available, although none cures the condition. Certain medications or Botox may be used in some cases, but more permanent relief is brought byesophageal dilatation and surgical cleaving of the muscle (Heller myotomy).
The most common form is primary achalasia, which has no known underlying cause. It is due to the failure of distal esophageal inhibitory neurons. However, a small proportion occurs secondary to other conditions, such as esophageal cancer or Chagas disease (an infectious disease common in South America).[4] Achalasia affects about one person in 100,000 per year.[4][5] There is no gender predominance for the occurrence of disease.[6] 

Signs and symptoms

The main symptoms of achalasia are dysphagia (difficulty in swallowing), regurgitation of undigested food, chest pain behind the sternum, and weight loss.[7] Dysphagia tends to become progressively worse over time and to involve both fluids and solids. Some people may also experience coughing when lying in a horizontal position. The chest pain experienced, also known as cardiospasm and non-cardiac chest pain can often be mistaken for a heart attack. It can be extremely painful in some sufferers. Food and liquid, including saliva, are retained in the esophagus and may be inhaled into the lungs (aspiration).

Mechanism

The cause of most cases of achalasia is unknown.[8] LES pressure and relaxation are regulated by excitatory (e.g., acetylcholine, substance P) and inhibitory (e.g., nitric oxide, vasoactive intestinal peptide) neurotransmitters. Persons with achalasia lack nonadrenergic, noncholinergic, inhibitory ganglion cells, causing an imbalance in excitatory and inhibitory neurotransmission. The result is a hypertensive nonrelaxed esophageal sphincter.[9]
Autopsy and myotomy specimens have, on histological examination, shown an inflammatory response consisting of CD3/CD8-positive cytotoxic T lymphocytes, variable numbers of eosinophils and mast cells, loss of ganglion cells, and neurofibrosis; these events appear to occur early in achalasia. Thus, it seems there is an autoimmune context to achalasia, most likely caused by viral triggers. Other studies suggest hereditary, neurodegenerative, genetic and infective contributions.[10]

Diagnosis

An axial CT image showing marked dilatation of the esophagus in a person with achalasia.
Due to the similarity of symptoms, achalasia can be mistaken for more common disorders such as gastroesophageal reflux disease (GERD), hiatus hernia, and even psychosomatic disorders. Specific tests for achalasia are barium swallow and esophageal manometry. In addition,endoscopy of the esophagus, stomach, and duodenum (esophagogastroduodenoscopy or EGD), with or without endoscopic ultrasound, is typically performed to rule out the possibility of cancer.[4]The internal tissue of the esophagus generally appears normal in endoscopy, although a "pop" may be observed as the scope is passed through the non-relaxing lower esophageal sphincterwith some difficulty, and food debris may be found above the LES.

Barium swallow

"Bird's beak" appearance and "megaesophagus," typical in achalasia.
The patient swallows a barium solution, with continuous fluoroscopy (X-ray recording) to observe the flow of the fluid through the esophagus. Normal peristaltic movement of the esophagus is not seen. There is acute tapering at the lower esophageal sphincter and narrowing at the gastro-esophageal junction, producing a "bird's beak" or "rat's tail" appearance. The esophagus above the narrowing is often dilated (enlarged) to varying degrees as the esophagus is gradually stretched over time.[4] An air-fluid margin is often seen over the barium column due to the lack of peristalsis. A five-minutes timed barium swallow can provide a useful benchmark to measure the effectiveness of treatment.

Esophageal manometry

Schematic of manometry in achalasia showing aperistalticcontractions, increased intraesophageal pressure, and failure of relaxation of the lower esophageal sphincter.
Because of its sensitivity, manometry (esophageal motility study) is considered the key test for establishing the diagnosis. A thin tube is inserted through the nose, and the patient is instructed to swallow several times. The probe measures muscle contractions in different parts of the esophagus during the act of swallowing. Manometry reveals failure of the LES to relax with swallowing and lack of functional peristalsis in the smooth muscle esophagus.[4]
Characteristic manometric findings are:[citation needed]
  • Lower esophageal sphincter (LES) fails to relax upon wet swallow (<75% relaxation)
  • Pressure of LES <26 mm Hg is normal,>100 is considered achalasia, > 200 is nut cracker achalasia.
  • Aperistalsis in esophageal body
  • Relative increase in intra-esophageal pressure as compared with intra-gastric pressure

Biopsy

Biopsy, the removal of a tissue sample during endoscopy, is not typically necessary in achalasia but if performed shows hypertrophied musculature and absence of certain nerve cells of themyenteric plexus, a network of nerve fibers that controls esophageal peristalsis.[11]

Treatment

Sublingual nifedipine significantly improves outcomes in 75% of people with mild or moderate disease. It was classically considered that surgical myotomy provided greater benefit than either botulinum toxin or dilation in those who fail medical management.[12] However, a recent randomized controlled trial found Pneumatic Dilation to be non-inferior to Laparoscopic Heller's Myotomy.[13]

Lifestyle changes

Both before and after treatment, achalasia patients may need to eat slowly, chew very well, drink plenty of water with meals, and avoid eating near bedtime. Raising the head off the bed or sleeping with a wedge pillow promotes emptying of the esophagus by gravity. After surgery or pneumatic dilatation, proton pump inhibitors are required to prevent reflux damage by inhibiting gastric acid secretion, and foods that can aggravate reflux, including ketchup, citrus, chocolate, alcohol, and caffeine, may need to be avoided.

Medication

Drugs that reduce LES pressure are useful. These include calcium channel blockers such as nifedipine[14] and nitrates such as isosorbide dinitrate and nitroglycerin. However, many patients experience unpleasant side effects such as headache and swollen feet, and these drugs often stop helping after several months.
Botulinum toxin (Botox) may be injected into the lower esophageal sphincter to paralyze the muscles holding it shut. As in the case of cosmetic Botox, the effect is only temporary and lasts about 6 months. Botox injections cause scarring in the sphincter which may increase the difficulty of later Heller myotomy. This therapy is recommended only for patients who cannot risk surgery, such as elderly persons in poor health.[4]

Pneumatic dilatation

In balloon (pneumatic) dilation or dilatation, the muscle fibers are stretched and slightly torn by forceful inflation of a balloon placed inside the lower esophageal sphincter. Gastroenterologists who specialize in achalasia have performed many of these forceful balloon dilatations and achieve better results and fewer perforations. There is always a small risk of a perforation which requires immediate surgical repair. Pneumatic dilatation causes some scarring which may increase the difficulty of Heller myotomy if the surgery is needed later. Gastroesophageal reflux (GERD) occurs after pneumatic dilatation in some patients. Pneumatic dilatation is most effective in the long term on patients over the age of 40; the benefits tend to be shorter-lived in younger patients. It may need to be repeated with larger balloons for maximum effectiveness.[5]

Surgery

Heller myotomy helps 90% of achalasia patients. It can usually be performed by a keyhole approach or laparoscopically.[15] The myotomy is a lengthwise cut along the esophagus, starting above the LES and extending down onto the stomach a little way. The esophagus is made of several layers, and the myotomy cuts only through the outside muscle layers which are squeezing it shut, leaving the inner muscosal layer intact. A partial fundoplication or "wrap" is generally added in order to prevent excessive reflux, which can cause serious damage to the esophagus over time. After surgery, patients should keep to a soft diet for several weeks to a month, avoiding foods that can aggravate reflux.
Most recommended fundoplication along with Heller's myotomy is Dor's fundoplication. It consists of 180 to 200 degree anterior wrap around the esophagus. It provides excellent result as compared to Nissen's fundoplication which is associated with higher incidence of the post surgery dysphagia.[16] Recent years, new treatmant modality is endoscopically POEM ( peroral endoscopic myotomy). This therapy modality has been performed since 2010. POEM did about 2500 patients.

Follow-up

Follow-up monitoring: Even after successful treatment of achalasia, swallowing may still deteriorate over time. The esophagus should be checked every year or two with a timed barium swallow because some may need pneumatic dilatations, a repeat myotomy, or evenesophagectomy after many years. In addition, some physicians recommend pH testing and endoscopy to check for reflux damage, which may lead to a premalignant condition known as Barrett's esophagus or a stricture if untreated.

Epidemiology

Incidence of achalasia is 1 to 2 per 200,000. Disease affects mostly adults between ages 30's and 50's.[

Accessory pancreas

Accessory pancreas
Classification and external resources
ICD-10Q45.3
ICD-9751.7
Accessory pancreas is a rare condition in which small groups of pancreatic cells are separate from the pancreas. They may occur in the mesentery of the small intestine, the wall of the duodenum, the upper part of the jejunum, or more rarely, in the wall of thestomachileumgallbladder or spleen. The condition was first described by Klob in 1859.[1]
Accessory pancreas is a small cluster of pancreas cells detached from the pancreas and sometimes found in the wall of the stomach or intestines.

Locality

After researching accessory pancreas at the University of Louisville medical library, I found a list of medical cases and the doctors that operated on the patients with this condition.
In 1904, Dr. A. S. Warthin found 47 cases in the literature and added 2. Up to 1921, 31 cases were added. Twelve cases were found at operation. A number of patients have been operated upon for this trouble since then. E. J. Horgan found 2 cases in 321 consecutive autopsies.

Warthin

Locality of Accessory Pancreas, A. S. Warthin, 1904:

Wall of stomach ………………… 14 Diverticulum of jejunum .......1
Wall of duodenum ………………. 12 Diverticulum of ileum ………………….… 4
Wall of jejunum …………………. 15 Meckel’s diverticulum …………………… 1
Wall of ileum ……………………. 1 Umbilical fistula ……………………….… 1
Wall of intestine …………………. 1 Mesenteric fat ……………………………. 1
Diverticulum of stomach …………. 1 Omentum ………………………………… 1

Horgan

Locality of Accessory Pancreas, E. J. Horgan from 1904-1921:

Stomach ………………………….. 5 Small intestine .…………………………….1
Pylorus ……………………………. 2 Diverticulum of intestine …………………. 4
Jejunum ………………………….. 13 Diverticulum of duodenum ………………. 2
Duodenum ………………………... 3 Splenic capsule …………………………… 1
Ileum ……………………………… 1

Diagnosis

As a nurse,inquire about the patient’s general health status because pancreatic disorders are often accompanied by weakness and fatigue. The past Medical history may reveal previous disorders of the biliary tract or duodenum, abdominal trauma or surgery, and metabolic disorders such as diabetes mellitus. The medication history should be detailed and specifically include the use of thiazides,furosemideestrogenscorticosteroids, sulfonamides, and opiates. Note a family history of pancreatic disorders. In the review of systems, obtain a complete description of any pain in the upper abdomen or epigastric area. Symptoms that may be important in relation to pancreatic disorders are pruritus, abdominal pain, dyspnea, nausea, and vomiting. The functional assessment includes data about the patient’s dietary habits and use of alcohol.
Note any restlessness, flushing, or diaphoresis during the examination. Vital signs may disclose low-grade fever, tachypnea, tachycardia, and hypotension. Inspect the skin for jaundice. Assess the abdomen for distention, tenderness, discoloration, and diminished bowel sounds.
Tests and procedures used to diagnose pancreatic disorders include laboratory analyses of blood, urine, stool, and pancreatic fluid, and imaging studies. Specific blood studies used to assess pancreatic function include measurements of serum amylase, lipase, glucose, calcium, and triglyceride levels. Urine amylase and renal amylase clearance tests may also be ordered. Stool specimens may be analyzed for fat content. The secretin stimulation test measures the bicarbonate concentration of pancreatic fluid after secretin is given intravenously to stimulate the production of pancreatic fluid.

Treatment

Treatment of accessory pancreas depends on the location and extent of the injured tissue. Surgery may be an option, or some physicians order prophylactic antibiotics.